2006;51:10818 ( (in Japanese) )
The continuous correlation of data with previous research enhances the plausibility of the stated advantages of GLP-1 RAs in the therapy of IIH
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
Constipation can build more slowly and persist as stomach and intestinal movement slows
The Bridge program is unique in that it offers a predictable $50 copayment that does not go up as dosages increase
Day 2: Semaglutide is reaching peak plasma concentration